RCAN1-mediated calcineurin inhibition as a target for cancer therapy

Cancer is the leading cause of mortality worldwide. Regulator of calcineurin 1 (RCAN1), as a patent endogenous inhibitor of calcineurin, plays crucial roles in the pathogenesis of cancers. Except for hypopharyngeal and laryngopharynx cancer, high expression of RCAN1 inhibits tumor progression. Molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lao, Mengyi, Zhang, Xiaozhen, Yang, Hanshen, Bai, Xueli, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206313/
https://www.ncbi.nlm.nih.gov/pubmed/35717152
http://dx.doi.org/10.1186/s10020-022-00492-7
_version_ 1784729311908986880
author Lao, Mengyi
Zhang, Xiaozhen
Yang, Hanshen
Bai, Xueli
Liang, Tingbo
author_facet Lao, Mengyi
Zhang, Xiaozhen
Yang, Hanshen
Bai, Xueli
Liang, Tingbo
author_sort Lao, Mengyi
collection PubMed
description Cancer is the leading cause of mortality worldwide. Regulator of calcineurin 1 (RCAN1), as a patent endogenous inhibitor of calcineurin, plays crucial roles in the pathogenesis of cancers. Except for hypopharyngeal and laryngopharynx cancer, high expression of RCAN1 inhibits tumor progression. Molecular antitumor functions of RCAN1 are largely dependent on calcineurin. In this review, we highlight current research on RCAN1 characteristics, and the interaction between RCAN1 and calcineurin. Moreover, the dysregulation of RCAN1 in various cancers is reviewed, and the potential of targeting RCAN1 as a new therapeutic approach is discussed.
format Online
Article
Text
id pubmed-9206313
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92063132022-06-19 RCAN1-mediated calcineurin inhibition as a target for cancer therapy Lao, Mengyi Zhang, Xiaozhen Yang, Hanshen Bai, Xueli Liang, Tingbo Mol Med Mini-Review Cancer is the leading cause of mortality worldwide. Regulator of calcineurin 1 (RCAN1), as a patent endogenous inhibitor of calcineurin, plays crucial roles in the pathogenesis of cancers. Except for hypopharyngeal and laryngopharynx cancer, high expression of RCAN1 inhibits tumor progression. Molecular antitumor functions of RCAN1 are largely dependent on calcineurin. In this review, we highlight current research on RCAN1 characteristics, and the interaction between RCAN1 and calcineurin. Moreover, the dysregulation of RCAN1 in various cancers is reviewed, and the potential of targeting RCAN1 as a new therapeutic approach is discussed. BioMed Central 2022-06-18 /pmc/articles/PMC9206313/ /pubmed/35717152 http://dx.doi.org/10.1186/s10020-022-00492-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Mini-Review
Lao, Mengyi
Zhang, Xiaozhen
Yang, Hanshen
Bai, Xueli
Liang, Tingbo
RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title_full RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title_fullStr RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title_full_unstemmed RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title_short RCAN1-mediated calcineurin inhibition as a target for cancer therapy
title_sort rcan1-mediated calcineurin inhibition as a target for cancer therapy
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206313/
https://www.ncbi.nlm.nih.gov/pubmed/35717152
http://dx.doi.org/10.1186/s10020-022-00492-7
work_keys_str_mv AT laomengyi rcan1mediatedcalcineurininhibitionasatargetforcancertherapy
AT zhangxiaozhen rcan1mediatedcalcineurininhibitionasatargetforcancertherapy
AT yanghanshen rcan1mediatedcalcineurininhibitionasatargetforcancertherapy
AT baixueli rcan1mediatedcalcineurininhibitionasatargetforcancertherapy
AT liangtingbo rcan1mediatedcalcineurininhibitionasatargetforcancertherapy

Ejemplares similares